GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Akeso presents positive results from registrational Phase III study of ivonescimab
ABL Diagnostics files bid to acquire IntegraGen
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Cipla partners with Qilu Pharmaceutical for licensing and supply of Keytruda biosimilar in US
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study